SI3137093T1 - Treatment and prevention of Alzheimer's disease - Google Patents
Treatment and prevention of Alzheimer's disease Download PDFInfo
- Publication number
- SI3137093T1 SI3137093T1 SI201530145T SI201530145T SI3137093T1 SI 3137093 T1 SI3137093 T1 SI 3137093T1 SI 201530145 T SI201530145 T SI 201530145T SI 201530145 T SI201530145 T SI 201530145T SI 3137093 T1 SI3137093 T1 SI 3137093T1
- Authority
- SI
- Slovenia
- Prior art keywords
- aluminum
- alzheimer
- oxyhydroxide
- disease
- oxihydroxide
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title claims abstract 4
- 208000024827 Alzheimer disease Diseases 0.000 title claims 9
- -1 aluminium oxyhydroxide Chemical compound 0.000 claims abstract 4
- 229910052782 aluminium Inorganic materials 0.000 claims 14
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 14
- FAHBNUUHRFUEAI-UHFFFAOYSA-M hydroxidooxidoaluminium Chemical compound O[Al]=O FAHBNUUHRFUEAI-UHFFFAOYSA-M 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 239000007983 Tris buffer Substances 0.000 claims 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000008139 complexing agent Substances 0.000 claims 1
- 239000003599 detergent Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229910021645 metal ion Inorganic materials 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 229940071643 prefilled syringe Drugs 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 150000005846 sugar alcohols Chemical class 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims 1
- 229960004906 thiomersal Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14166355 | 2014-04-29 | ||
| EP14166354 | 2014-04-29 | ||
| EP15720059.3A EP3137093B1 (en) | 2014-04-29 | 2015-04-29 | Treatment and prevention of alzheimer's disease (ad) |
| PCT/EP2015/059339 WO2015165966A1 (en) | 2014-04-29 | 2015-04-29 | Treatment and prevention of alzheimer's disease (ad) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3137093T1 true SI3137093T1 (en) | 2018-01-31 |
Family
ID=53039896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201530145T SI3137093T1 (en) | 2014-04-29 | 2015-04-29 | Treatment and prevention of Alzheimer's disease |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10478454B2 (enExample) |
| EP (2) | EP3269376B1 (enExample) |
| JP (1) | JP6692755B2 (enExample) |
| KR (1) | KR102388363B1 (enExample) |
| CN (1) | CN106659738B (enExample) |
| AU (1) | AU2015254663B2 (enExample) |
| CA (1) | CA2946928C (enExample) |
| CY (1) | CY1119674T1 (enExample) |
| DK (1) | DK3137093T3 (enExample) |
| ES (2) | ES2824763T3 (enExample) |
| HR (1) | HRP20171896T1 (enExample) |
| HU (1) | HUE037501T2 (enExample) |
| LT (1) | LT3137093T (enExample) |
| NO (1) | NO3137093T3 (enExample) |
| PL (1) | PL3137093T3 (enExample) |
| PT (1) | PT3137093T (enExample) |
| SI (1) | SI3137093T1 (enExample) |
| WO (1) | WO2015165966A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106535924A (zh) | 2014-04-29 | 2017-03-22 | 阿费里斯股份公司 | 阿尔茨海默病(ad)的治疗和预防 |
| KR102506460B1 (ko) * | 2014-04-29 | 2023-03-03 | 어드밴티지 테라퓨틱스, 인코포레이티드 | 알츠하이머병（ａｄ）의 치료 및 예방 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994016327A1 (en) * | 1993-01-14 | 1994-07-21 | Pollard Harvey B | Methods and compositions for blocking amyloid protein ion channels |
| EP1007040B1 (en) * | 1997-08-21 | 2002-05-08 | P.N. Gerolymatos S.A. | Use of phanquinone for the treatment of alzheimer's disease |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| CN104436212A (zh) * | 2010-03-29 | 2015-03-25 | 诺华股份有限公司 | 包含与病毒样颗粒偶联的淀粉样β1-6肽及佐剂的组合物 |
| CN106535924A (zh) * | 2014-04-29 | 2017-03-22 | 阿费里斯股份公司 | 阿尔茨海默病(ad)的治疗和预防 |
| KR102506460B1 (ko) * | 2014-04-29 | 2023-03-03 | 어드밴티지 테라퓨틱스, 인코포레이티드 | 알츠하이머병（ａｄ）의 치료 및 예방 |
-
2015
- 2015-04-29 WO PCT/EP2015/059339 patent/WO2015165966A1/en not_active Ceased
- 2015-04-29 PT PT157200593T patent/PT3137093T/pt unknown
- 2015-04-29 AU AU2015254663A patent/AU2015254663B2/en active Active
- 2015-04-29 DK DK15720059.3T patent/DK3137093T3/en active
- 2015-04-29 HU HUE15720059A patent/HUE037501T2/hu unknown
- 2015-04-29 US US15/307,082 patent/US10478454B2/en active Active
- 2015-04-29 SI SI201530145T patent/SI3137093T1/en unknown
- 2015-04-29 ES ES17189527T patent/ES2824763T3/es active Active
- 2015-04-29 EP EP17189527.9A patent/EP3269376B1/en active Active
- 2015-04-29 LT LTEP15720059.3T patent/LT3137093T/lt unknown
- 2015-04-29 ES ES15720059.3T patent/ES2651537T3/es active Active
- 2015-04-29 CA CA2946928A patent/CA2946928C/en active Active
- 2015-04-29 NO NO15720059A patent/NO3137093T3/no unknown
- 2015-04-29 EP EP15720059.3A patent/EP3137093B1/en active Active
- 2015-04-29 KR KR1020167033332A patent/KR102388363B1/ko active Active
- 2015-04-29 JP JP2016565267A patent/JP6692755B2/ja active Active
- 2015-04-29 CN CN201580029861.5A patent/CN106659738B/zh active Active
- 2015-04-29 HR HRP20171896TT patent/HRP20171896T1/hr unknown
- 2015-04-29 PL PL15720059T patent/PL3137093T3/pl unknown
-
2017
- 2017-12-13 CY CY20171101303T patent/CY1119674T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3269376A1 (en) | 2018-01-17 |
| ES2824763T3 (es) | 2021-05-13 |
| AU2015254663A1 (en) | 2016-11-10 |
| CN106659738B (zh) | 2021-02-09 |
| HRP20171896T1 (hr) | 2018-02-23 |
| PL3137093T3 (pl) | 2018-06-29 |
| CA2946928A1 (en) | 2015-11-05 |
| KR20160145822A (ko) | 2016-12-20 |
| ES2651537T3 (es) | 2018-01-29 |
| KR102388363B1 (ko) | 2022-04-19 |
| DK3137093T3 (en) | 2017-12-11 |
| AU2015254663B2 (en) | 2020-04-02 |
| CN106659738A (zh) | 2017-05-10 |
| PT3137093T (pt) | 2017-12-19 |
| EP3137093B1 (en) | 2017-09-13 |
| HUE037501T2 (hu) | 2018-08-28 |
| EP3137093A1 (en) | 2017-03-08 |
| CY1119674T1 (el) | 2018-04-04 |
| JP2017518275A (ja) | 2017-07-06 |
| JP6692755B2 (ja) | 2020-05-13 |
| CA2946928C (en) | 2023-01-31 |
| LT3137093T (lt) | 2017-12-11 |
| WO2015165966A1 (en) | 2015-11-05 |
| EP3269376B1 (en) | 2020-07-15 |
| NO3137093T3 (enExample) | 2018-02-10 |
| US20170049812A1 (en) | 2017-02-23 |
| US10478454B2 (en) | 2019-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2849758T1 (en) | Compositions comprising zoledronic acid or related compounds for relieving inflammatory pain and related conditions | |
| WO2011118976A3 (en) | Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same | |
| AR093106A1 (es) | Silicato de zirconio microporoso para el tratamiento de la hipercalemia | |
| WO2013158680A3 (en) | Compositions and methods comprising celecoxib or related compounds and dextromethorphan | |
| HRP20171512T1 (hr) | Derivati betulina | |
| EP4371615A3 (en) | Treatment of amd using aav sflt-1 | |
| EA201492021A1 (ru) | Антительный состав | |
| AR082150A1 (es) | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio | |
| JP2015525763A5 (enExample) | ||
| HRP20110800T1 (hr) | UPORABA 2-6-(3-AMINO-PIPERIDIN-1-IL)-3-METIL-2,4-DIOKSO-3,4-DIHIDRO-2H-PIRIMIDIN-1-ILMETIL-4-FLUORO-BENZONITRILA ZA LIJEČENJE DIJABETESA, RAKA, AUTOIMUNIH POREMEĆAJA I ZARAZE HIV-om | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| MY169099A (en) | Injectable formulation | |
| EP4342473A3 (en) | Compounds useful in hiv therapy | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| EA201791138A1 (ru) | Фармацевтическая композиция, ее приготовление и применения | |
| SI3099307T1 (en) | Use of cladribine for the treatment of neuromyelitis of the visual nerve | |
| SI3137093T1 (en) | Treatment and prevention of Alzheimer's disease | |
| FI3137094T3 (fi) | Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen | |
| JP2017515812A5 (enExample) | ||
| JP2019531286A5 (enExample) | ||
| JP2017514831A5 (enExample) | ||
| JP2012526099A5 (enExample) | ||
| JP2017518275A5 (enExample) | ||
| JP2015524808A5 (enExample) | ||
| JP2013533304A5 (enExample) |